Showing 2601-2610 of 5617 results for "".
- Low-Dose Naltrexone in Major Depressive Disorder: Trial Findingshttps://reachmd.com/news/low-dose-naltrexone-mdd/2487123/Key Takeaways In patients with moderate major depressive disorder, adjunctive low-dose naltrexone was not associated with greater improvement than placebo. No effect was seen on hsCRP or on BDI-II, BADS, SF-36, POMS, and SicknessQ measures, and baselin
- Aesthetic Meet 2026: The Aesthetic Society Names Dr. Jamil Ahmad Presidenthttps://reachmd.com/news/aesthetic-meet-2026-the-aesthetic-society-names-dr-jamil-ahmad-president/2487120/The Aesthetic Society has named Jamil Ahmad, MD, as its President, and The Aesthetic Foundation has named David A. Sieber, MD, as President, during The Aesthetic MEET 2026 in Boston. Dr. Ahmad assumes leadership as The Society reports membership growth of more than 30%, with new members fr
- SCALE 2026: Dermatologists Navigate the Expanding Role of GLP-1 RAs in Skin Health and Aesthetic Carehttps://reachmd.com/news/scale-2026-dermatologists-navigate-the-expanding-role-of-glp-1s-in-skin-health-and-aesthetic-care/2487119/Dermatologists Navigate the Expanding Role of GLP-1 RAs in Skin Health and Aesthetic Care As use of GLP-1 receptor agonists (RAs) continues to surge, dermatologists are increasingly encountering the downstream effects of these medications in both medical and cosmetic pract
- From SCALE 2026: Dermatologists Navigate the Expanding Role of GLP-1s in Skin Health and Aesthetic Carehttps://reachmd.com/news/dermatologists-navigate-the-expanding-role-of-glp-1s-in-skin-health-and-aesthetic-care/2487095/As use of GLP-1 receptor agonists continues to surge, dermatologists are increasingly encountering the downstream effects of these medications in both medical and cosmetic practice. During a session at the 2026 Music City SCALE meeting in Nashville, dermatologist and researcher Glynis Ablon, MD,
- LaserAway Marks 20 Years with Continued National Expansionhttps://reachmd.com/news/laseraway-marks-20-years-with-continued-national-expansion/2487069/LaserAway is celebrating its 20th anniversary alongside continued national expansion and recent recognition within the aesthetics industry. The company, which specializes in aesthetic dermatology services, announced that it now operates more than 215 clinics across the United States. The c
- Topical NAC Plus Doxycycline Shows Benefit in Moderate Acnehttps://reachmd.com/news/topical-nac-plus-doxycycline-shows-benefit-in-moderate-acne/2486948/Topical N-acetylcysteine (NAC) plus doxycycline was associated with greater improvement than benzoyl peroxide (BPO) plus doxycycline in patients
- 12-Month Data Support Durability of Click-Crosslinked HA for Nasolabial Foldhttps://reachmd.com/news/12-month-data-support-durability-of-click-crosslinked-ha-for-nasolabial-fold/2486822/A novel long-chain hyaluronic acid (HA) filler utilizing click-chemistry crosslinking demonstrated sustained efficacy and a favorable safety profile for nasolabial fold (NLF) correction in 2 prospective studies published in the Journal of Cosmetic Dermatology. Traditional HA fille
- FDA Flags Six Additional Gel Nail Removers for Banned Chemicalhttps://reachmd.com/news/fda-flags-six-additional-gel-nail-removers-for-banned-chemical/2486820/The US Food and Drug Administration (FDA) has identified six additional cosmetic products marketed as gel nail polish removers that contain methylene chloride, a substance prohibited for use in cosmetics, according to a statement from the agency.</
- CORAL Trial: Oral Nalbuphine Reduces Cough in IPFhttps://reachmd.com/news/oral-nalbuphine-cough-ipf-coral-trial/2486679/Key Takeaways In the CORAL trial, three nalbuphine ER doses were associated with greater objective cough reduction than placebo at week 6. Patient-reported cough frequency improved versus placebo in the 54-mg and 108-mg groups, while the 27-mg group di
- Evaluating a Peer Navigator Intervention for Opioid-Related Overdosehttps://reachmd.com/news/peer-navigator-intervention-opioid-overdose/2486633/Key Takeaways: In a randomized four-site emergency department trial, investigators found no significant difference in opioid-related adverse events between a peer navigator intervention and site-directed care. The Relay model began in the emergency dep